A Strong Close to 2018... let's say 2019 will be interesting
I started my career in Life Sciences 20 years ago and except the biotech bubble of 1999-2000, 2018 was probably the most exciting year in the sector. We saw a record number of IPOs, pharmaceutical licensing deals, FDA approvals and some of the most exciting breakthroughs in medicine. It was also a phenomenal year for our clients, partners and investment portfolio companies.
2019 promises to be different. The stock market is in correction and yesterday morning's Bristol-Myers Squibb acquisition of Celgene indicates that we will expect more large pharma mega-mergers in 2019. This would potentially mean less smaller licensing deals - especially in areas larger pharmaceuticals were competing against each other. More than ever, it's important to network and find quality partners for your pipeline.
With J.P. Morgan Healthcare Conference starting in the first week of January 2019, we have developed the most comprehensive guide to all of the satellite networking sessions around the event.
Remember, your network is your net worth.
We look forward to seeing you at some of these sessions and look forward to working with you in the new year.